Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLPG Galapagos	$31.79 +1.1%	$30.71	$22.36 ▼ $33.86	N/A	0.1	327,135 shs	158,220 shs
IDYA IDEAYA Biosciences	$24.86 +0.6%	$23.02	$13.45 ▼ $40.25	$2.18B	0.09	1.14 million shs	589,699 shs
RAPP Rapport Therapeutics	$16.01 +9.4%	$13.84	$6.43 ▼ $29.74	$584.33M	0.62	188,150 shs	427,328 shs
SRPT Sarepta Therapeutics	$18.26 +1.1%	$17.93	$10.41 ▼ $140.97	$1.78B	0.46	6.28 million shs	7.94 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLPG Galapagos	-1.75%	-4.47%	-3.71%	+8.53%	+21.44%
IDYA IDEAYA Biosciences	-1.63%	-0.16%	+0.86%	+27.24%	-37.43%
RAPP Rapport Therapeutics	-0.95%	+0.27%	-8.85%	+45.72%	-34.39%
SRPT Sarepta Therapeutics	-10.68%	-13.96%	+51.38%	-52.91%	-87.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLPG Galapagos	0.1258 of 5 stars	0.7	2.0	0.0	0.6	0.0	0.6
IDYA IDEAYA Biosciences	4.4167 of 5 stars	4.4	3.0	4.4	2.3	1.7	0.0
RAPP Rapport Therapeutics	1.7584 of 5 stars	3.5	0.0	0.0	2.1	1.7	0.6
SRPT Sarepta Therapeutics	4.5433 of 5 stars	4.0	2.0	4.2	1.8	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLPG Galapagos	1.38	Strong Sell	$25.33	-20.31% Downside
IDYA IDEAYA Biosciences	2.77	Moderate Buy	$48.09	93.45% Upside
RAPP Rapport Therapeutics	3.00	Buy	$29.50	84.26% Upside
SRPT Sarepta Therapeutics	2.07	Hold	$43.50	138.23% Upside

Current Analyst Ratings Breakdown

Latest RAPP, GLPG, IDYA, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
8/20/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$17.00
8/15/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$12.00
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
8/6/2025	RAPP Rapport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
8/5/2025	GLPG Galapagos	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Sell
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLPG Galapagos	$298.31M	N/A	$0.72 per share	44.07	$47.57 per share	N/A
IDYA IDEAYA Biosciences	$7M	311.25	N/A	N/A	$12.25 per share	2.03
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.35 per share	N/A
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.20 per share	8.30	$15.99 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	10/22/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	11/3/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$2.50	N/A	N/A	N/A	N/A	-29.99%	-28.64%	11/6/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.67	N/A	-2.34%	-1.03%	-0.37%	11/5/2025 (Estimated)

Latest RAPP, GLPG, IDYA, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	-$0.75	+$0.12	-$0.75	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLPG Galapagos	N/A	8.08	7.99
IDYA IDEAYA Biosciences	N/A	12.39	12.39
RAPP Rapport Therapeutics	N/A	22.75	22.75
SRPT Sarepta Therapeutics	0.84	2.89	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLPG Galapagos	32.46%
IDYA IDEAYA Biosciences	98.29%
RAPP Rapport Therapeutics	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
GLPG Galapagos	2.91%
IDYA IDEAYA Biosciences	2.50%
RAPP Rapport Therapeutics	13.57%
SRPT Sarepta Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.45 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	31.55 million	N/A
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable

RAPP, GLPG, IDYA, and SRPT Headlines

Recent News About These Companies

University of Wisconsin Foundation Buys Shares of 27,717 Sarepta Therapeutics, Inc. $SRPT

August 26 at 7:23 AM | marketbeat.com

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT

August 26 at 5:06 AM | theglobeandmail.com

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

August 25 at 4:42 PM | globenewswire.com

Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns

August 25 at 1:56 PM | finance.yahoo.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

August 25 at 1:56 PM | tmcnet.com

Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics

August 25 at 1:56 PM | benzinga.com

SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline

August 25 at 12:04 PM | globenewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

August 25 at 11:51 AM | mms.businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 25 at 10:38 AM | globenewswire.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm

August 25 at 8:45 AM | prnewswire.com

Sarepta Therapeutics (SRPT) Rating Update: HC Wainwright & Co. ...

August 25 at 8:30 AM | gurufocus.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. ...

August 25 at 4:30 AM | gurufocus.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. ...

August 25 at 4:30 AM | gurufocus.com

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

August 25 at 3:11 AM | prnewswire.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 25 at 3:10 AM | prnewswire.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 24 at 4:00 PM | globenewswire.com

Sarepta Therapeutics, Inc. $SRPT Shares Bought by T. Rowe Price Investment Management Inc.

August 24 at 6:16 AM | marketbeat.com

SRPT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important ...

August 24 at 3:09 AM | barrons.com

SA analyst upgrades/downgrades: XPENG, GOOG, MNSO, SRPT

August 23 at 5:03 PM | msn.com

SRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class Action

August 23 at 4:48 PM | globenewswire.com

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

August 23 at 7:08 AM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RAPP, GLPG, IDYA, and SRPT Company Descriptions

Galapagos NASDAQ:GLPG

$31.79 +0.35 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$31.83 +0.04 (+0.13%)

As of 04:10 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

IDEAYA Biosciences NASDAQ:IDYA

$24.86 +0.15 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$24.86 +0.00 (+0.02%)

As of 04:11 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Rapport Therapeutics NASDAQ:RAPP

$16.01 +1.38 (+9.43%)

Closing price 04:00 PM Eastern

Extended Trading

$16.20 +0.19 (+1.19%)

As of 05:12 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Sarepta Therapeutics NASDAQ:SRPT

$18.26 +0.20 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$18.43 +0.17 (+0.93%)

As of 05:28 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time